While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

Sequana Medical announces 2024 Full Year Results and 2025 Outlookalfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...